- Coordinator
- Institut National De La Sante Et De La Recherche Medicale, France
- Runs
- 1 January 2024 to 31 December 2028
- Status
- Running
- EU funding
- €6.2m
- Total cost
- €6.3m
- Partners
- 17 organisations in 9 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101136365
What the project is doing
In the project's own words, from its summary on CORDIS.
The evaluation of new medicines for rare diseases (RD) including rare paediatric RDs is challenging for several reasons, among which are the small patient sample sizes, heterogeneity of patients and diseases and heterogeneity in disease knowledge. Due to these difficulties, access to effective treatments and the number of treatment options are often limited in RDs. INVENTS aims to provide clinical trial trialists, researchers and regulators with a global framework encompassing methods, workflows and evidence assessment tools to be implemented in orphan and paediatric drug development.
Our ambition is to significantly improve the evaluation of evidence and regulatory decision-making through the development and validation of: refined longitudinal model-based diseases trajectories and treatment effect, improved extrapolation models, in silico trials (e.g., virtual patient cohorts), optimised model-based clinical trial designs and evidence synthesis methods. These will be evaluated through simulation studies and tested on extensive data from a range of use cases provided by our industrial partners Roche and Novartis and Real World data (RWD) from RD registry.
The INVENTS framework will improve consistency and efficiency of the drug evaluation process for RD by augmenting clinical evidence without compromising its scientific integrity and providing regulators assessment credibility criteria. At the end of this 5 years project, the European industry will be able to exploit novel and improved clinical trial designs, in silico trials and RWD analysis approaches supporting drug development in RD.
The European Medicine Agency and European national regulators (including Health Technology Assessment bodies) will be supplied with a general framework allowing better informed decision-making. Most importantly, RD patients will benefit from an increased and faster access to efficacious and safe treatments.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Coordinator |
| Medizinische Universitaet Wien | Wien | Austria | Participant |
| F. Hoffmann-La Roche AG | Basel | Switzerland | Associatedpartner |
| Novartis Pharma AG | Basel | Switzerland | Associatedpartner |
| Masarykova univerzita | Brno | Czechia | Third party |
| Universitaetsmedizin Goettingen - Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen Rechts | Goettingen | Germany | Participant |
| Assistance Publique Hopitaux De Paris | Paris | France | Participant |
| Ecrin European Clinical Research Infrastructure Network | Paris | France | Participant |
| Inserm Transfert SA | Paris | France | Participant |
| Plateforme Des Donnees De Sante | Paris | France | Participant |
| Fondazione per La Ricerca Farmacologica Gianni Benzi Ets | Valenzano | Italy | Third party |
| Teddy European Network of Excellence for Paediatric Research | Bari | Italy | Participant |
| Stichting Radboud Universitair Medisch Centrum | Nijmegen | Netherlands | Participant |
| Lakemedelsverket | Uppsala | Sweden | Participant |
| Pharmetheus AB | Uppsala | Sweden | Participant |
| Uppsala Universitet | Uppsala | Sweden | Participant |
| University of Warwick | Coventry | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI